Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenalidomide Based Immunotherapy Efficacy Related Molecular Biomarker in Diffuse Large B-cell Lymphoma

NCT03715296 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT03715296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03715296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenalidomide Based Immunotherapy Efficacy Related Molecular Biomarker in Diffuse Large B-cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 18, 2018
Completion date
September 15, 2020
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma